Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Dana M. Roque"'
Autor:
Dana M. Roque, Eric R. Siegel, Natalia Buza, Stefania Bellone, Gloria S. Huang, Gary Altwerger, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Gautam G. Rao, Elena Ratner, Alessandro D. Santin
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-7 (2024)
Abstract Background Ixabepilone may retain activity in paclitaxel-resistant disease. We previously reported improved response rates (ORR), progression-free (PFS), and overall survival (OS) conferred by ixabepilone+bevacizumab (IXA + BEV) compared to
Externí odkaz:
https://doaj.org/article/f49671ab396045a1849b78083c690bd0
Autor:
Aaron Sorrin, Anika Dasgupta, Kathryn McNaughton, Carla Arnau Del Valle, Keri Zhou, Cindy Liu, Dana M. Roque, Huang Chiao Huang
Publikováno v:
Cell & Bioscience, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Background Within the last decade, poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged in the clinic as an effective treatment for numerous malignancies. Preclinical data have demonstrated powerful combination effects of PARPi paired
Externí odkaz:
https://doaj.org/article/08d7f55994df4fa88fbdc1cd599786e3
Autor:
Aaron J. Sorrin, Keri Zhou, Katherine May, Cindy Liu, Kathryn McNaughton, Idrisa Rahman, Barry J. Liang, Imran Rizvi, Dana M. Roque, Huang-Chiao Huang
Publikováno v:
iScience, Vol 26, Iss 8, Pp 107221- (2023)
Summary: Circulating drugs in the peritoneal cavity is an effective strategy for advanced ovarian cancer treatment. Photoimmunotherapy, an emerging modality with potential for the treatment of ovarian cancer, involves near-infrared light activation o
Externí odkaz:
https://doaj.org/article/c8c25852cd1e49fb9406a86e1e47471f
Autor:
Ariel E. Pollock, MD, Hunter Risher, BS, Melanie Berger, MD, Dana M. Roque, MD, Gautam Rao, MD, Elizabeth M. Nichols, MD, Pranshu Mohindra, MD, MMM
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 4, Pp 101191- (2023)
Purpose: Pelvic reirradiation (re-RT) for patients with gynecologic cancers remains a challenge because of toxicity concerns. Given the dosimetric advantages of proton therapy, we aimed to assess oncologic and toxicity outcomes of patients with re-RT
Externí odkaz:
https://doaj.org/article/c6eeeac819ca4e539b0b6b8a0c7219ce
Autor:
Yan Baglo, Aaron J. Sorrin, Xiaocong Pu, Cindy Liu, Jocelyn Reader, Dana M. Roque, Huang-Chiao Huang
Publikováno v:
Translational Oncology, Vol 14, Iss 11, Pp 101198- (2021)
P-glycoprotein (P-gp) is an adenosine triphosphate (ATP)-dependent drug efflux protein commonly associated with multidrug resistance in cancer chemotherapy. In this report, we used a dual-fluorescent co-culture model to study the population dynamics
Externí odkaz:
https://doaj.org/article/b3f0b984c71d4adc9972dd0a19832dff
Autor:
Michael Ha, Abigail Drees, Madalyn Myers, Emily R. Finkelstein, Mary Dandulakis, Maxine Reindorf, Dana M. Roque, Stephanie A. Beall, Sheri Slezak, Yvonne M. Rasko
Publikováno v:
Journal of Assisted Reproduction and Genetics. 40:581-587
Infertility affects one in eight women in the USA. In vitro fertilization (IVF) is an effective but costly treatment that lacks uniform insurance coverage. We evaluated the current insurance coverage landscape for IVF in America.We conducted a cross-
Publikováno v:
International Journal of STD & AIDS. 33:954-962
Objectives To describe risk factors/incidence of abnormal cervical/vaginal cytology/histology and cancer among women living with human immunodeficiency virus (WLHIV) ≥65 years compared to HIV-negative matched controls Study Design Retrospective coh
Autor:
Ghanshyam Yadav, Dana M. Roque, Stefania Bellone, Diego D. Manavella, Tobias M.P. Hartwich, Margherita Zipponi, Justin Harold, Joan Tymon-Rosario, Levent Mutlu, Gary Altwerger, Gulden Menderes, Elena Ratner, Natalia Buza, Pei Hui, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Ludmil B. Alexandrov, Alessandro D. Santin
Publikováno v:
Gynecologic Oncology. 166:351-357
Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer with a poor prognosis. Approximately 30% of USC overexpress HER2/neu, a recognized target for trastuzumab in advanced/recurrent HER2/neu-positive USC. We evaluated the effi
Autor:
Alessandro D. Santin, Peter E. Schwartz, Dan-Arin Silasi, Elena Ratner, Babak Litkouhi, Masoud Azodi, Stefania Bellone, Paul Celano, Karim ElSahwi, William Lowery, Dirk Pikaart, Babak Edraki, Nicole Nevadunsky, Floor J. Backes, David M. O'Malley, Laura Havrilesky, Angeles Alvarez Secord, Setsuko Chambers, Osama Abdelghany, Pei Hui, Natalia Buza, Eric Siegel, Dana M. Roque, Amanda N. Fader
Full Protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c92ca00b0a5ecbda5f494fdb1197319
https://doi.org/10.1158/1078-0432.22477524.v1
https://doi.org/10.1158/1078-0432.22477524.v1
Autor:
Alessandro D. Santin, Peter E. Schwartz, Dan-Arin Silasi, Elena Ratner, Babak Litkouhi, Masoud Azodi, Stefania Bellone, Paul Celano, Karim ElSahwi, William Lowery, Dirk Pikaart, Babak Edraki, Nicole Nevadunsky, Floor J. Backes, David M. O'Malley, Laura Havrilesky, Angeles Alvarez Secord, Setsuko Chambers, Osama Abdelghany, Pei Hui, Natalia Buza, Eric Siegel, Dana M. Roque, Amanda N. Fader
Purpose:Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carboplat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::702e80cf4af1c3371d5dd83dcd69a7eb
https://doi.org/10.1158/1078-0432.c.6529689
https://doi.org/10.1158/1078-0432.c.6529689